A White Paper—Consensus and Recommendations of a Global Harmonization Team on Assessing the Impact of Immunogenicity on Pharmacokinetic Measurements

The Global Bioanalysis Consortium (GBC) set up an international team to explore the impact of immunogenicity on pharmacokinetic (PK) assessments. The intent of this paper is to define the field and propose best practices when developing PK assays for biotherapeutics. We focus on the impact of anti-drug antibodies (ADA) on the performance of PK assay leading to the impact on the reported drug concentration and exposure. The manuscript describes strategies to assess whether the observed change in the drug concentration is due to the ADA impact on drug clearance rates or is a consequence of ADA interference in the bioanalytical method applied to measure drug concentration. This paper provides the bioanalytical scientist guidance for developing ADA-tolerant PK methods. It is essential that the data generated in the PK, ADA, pharmacodynamic and efficacy/toxicity evaluations are viewed together. Therefore, the extent for the investigation of the PK sensitivity to the presence of ADA should be driven by the project needs and risk based.

[1]  Deqin Sun,et al.  Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. , 2007, Regulatory toxicology and pharmacology : RTP.

[2]  Iain Gardner,et al.  Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies , 2013, Clinical Pharmacokinetics.

[3]  Jean W. Lee,et al.  Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. , 2010, Journal of pharmaceutical and biomedical analysis.

[4]  B. Dijkmans,et al.  Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[5]  Eugen Koren,et al.  An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. , 2005, Journal of immunological methods.

[6]  P. Bonate,et al.  Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme® , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  Eric Woolf,et al.  Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples , 2007, The AAPS Journal.

[8]  Boris Gorovits,et al.  Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation , 2013, The AAPS Journal.

[9]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[10]  Afshin Safavi,et al.  Ligand Binding Assays in the 21st Century Laboratory: Platforms , 2012, The AAPS Journal.

[11]  K. Roux,et al.  Idiotypic–anti‐idiotypic complexes and their in vivo metabolism , 2002, Cancer.

[12]  Yaoli Song,et al.  Effects of PEGylation and Immune Complex Formation on the Pharmacokinetics and Biodistribution of Recombinant Interleukin 10 in Mice , 2012, Drug Metabolism and Disposition.

[13]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[14]  J. Sailstad,et al.  Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. , 2011, Bioanalysis.

[15]  Yong-Sung Kim,et al.  Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. , 2007, Journal of molecular biology.

[16]  Olivier Heudi,et al.  Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. , 2008, Analytical chemistry.

[17]  Surinder Kaur,et al.  Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. , 2013, Bioanalysis.

[18]  P. Lachmann,et al.  Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. , 1997, European journal of immunology.

[19]  J. Pérez-Ruixo,et al.  Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis , 2011, Clinical pharmacokinetics.

[20]  J. Pérez-Ruixo,et al.  Immunogenicity of panitumumab in combination chemotherapy clinical trials , 2011, BMC clinical pharmacology.

[21]  P. Lachmann,et al.  A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes , 1995, Clinical and experimental immunology.

[22]  C. Wagner,et al.  Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys , 2005, Journal of Pharmacology and Experimental Therapeutics.

[23]  Heather Myler,et al.  Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.

[24]  M. Borggrefe,et al.  Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies. , 2002, Seminars in thrombosis and hemostasis.

[25]  L. Howes,et al.  Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer , 2011, BMC clinical pharmacology.

[26]  P. Vicini,et al.  A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics , 2013, The AAPS Journal.

[27]  M. Tomonaga,et al.  Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody , 2001, International journal of hematology.

[28]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[29]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[30]  Yow-Ming C Wang,et al.  Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors , 2009, Journal of clinical pharmacology.

[31]  Guodong Chen,et al.  Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies , 2011, Analytical and Bioanalytical Chemistry.

[32]  L. Wilkins.  Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study , 2010, Neurology.

[33]  E. Martı́n-Mola,et al.  Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. , 2011, Rheumatology.

[34]  P. Anderson.  Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. , 2005, Seminars in arthritis and rheumatism.

[35]  Hendrik Neubert,et al.  Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. , 2008, Analytical chemistry.

[36]  J. P. Perez Ruixo,et al.  The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics , 2012, The AAPS Journal.

[37]  Binodh DeSilva,et al.  Bioanalytical Method Validation for Macromolecules in Support of Pharmacokinetic Studies , 2005, Pharmaceutical Research.

[38]  J. Pérez-Ruixo,et al.  Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours , 2012, Clinical Pharmacokinetics.

[39]  L. Kappos,et al.  Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. , 2005 .

[40]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[41]  Thomas Layloff,et al.  Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies , 1992 .

[42]  Vinod P. Shah,et al.  Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.

[43]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[44]  Jana S Chain,et al.  An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. , 2007, Journal of immunological methods.

[45]  B. Bénichou,et al.  A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. , 2009, Molecular genetics and metabolism.

[46]  Thomas Layloff,et al.  Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies , 1992 .

[47]  R. Faggioni,et al.  PK-PD modeling of protein drugs: implications in assay development. , 2011, Bioanalysis.

[48]  Viswanath Devanarayan,et al.  Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.

[49]  Arunan Kaliyaperumal,et al.  Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab , 2007, The Journal of Immunology.

[50]  L. Roskos,et al.  Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab , 2010, Clinical pharmacokinetics.

[51]  Mark Ma,et al.  Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment , 2013, The AAPS Journal.